Sharipov, R.A.,
Omarov, M.A.,
Mulyukov, A.R.,
Dybova, A.I.,
Vyaseleva, E.T.,
Kayumova, N.B.,
Saitgalina, A. Sh.,
Ententeev, K.R.,
Iagafarov, I.R.,
Kuserbaev, I.V.,
Gubaeva, E.A. (2023) thorough
safety assessment of modern genetic manipulations, and the integrated participation of specialists
Beylerli, Ozal,
Tamrazov, Rasim,
Gareev, Ilgiz,
Ilyasova, Tatiana,
Shumadalova, Alina,
Bai, Yunlong,
Yang, Baofeng (2023) of their diagnostic and prognostic value, and optimization of their therapeutic efficacy and
safety. This review aims
Zhiyong, Ji,
Yeping, Ling,
Pingbo, Chen,
Meng, Yuxiao,
Xu, Shancai,
Wu, Pei,
Wang, Chunlei,
Ilyasova, Tatiana,
Sun, Bowen,
Shi, Huaizhang (2023)
in reasonably selected patients. The perioperative
safety is within the
acceptable range. Before 51 days
Bikbov, Mukharram M.,
Kazakbaeva, Gyulli M.,
Holz, Frank G.,
Panda-Jonas, Songhomitra,
Gilemzianova, Leisan I.,
Khakimov, Dinar A.,
Jonas, Jost B. (2023) the intraocular tolerability and
safety of a fully human monoclonal IgG2-antibody against EGFR, already